All Stories

Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer

Ono pays $280M upfront for Ionis' antisense oligonucleo...

Mar 12, 2025 0

Japan's Ono Pharmaceutical is paying $280 million upfront to acquire Ionis Pharm...

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to co-develop amylin asset

Roche pads out obesity pipeline, paying Zealand $1.6B u...

Mar 12, 2025 0

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning...

Boehringer Ingelheim teams with Veeva to launch new R&D platform One Medicine

Boehringer Ingelheim teams with Veeva to launch new R&D...

Mar 12, 2025 0

Boehringer Ingelheim and software firm Veeva Systems have launched Boehringer’s ...

NIH grants powered $94B in economic activity in 2024 and supported more than 400K jobs: report

NIH grants powered $94B in economic activity in 2024 an...

Mar 11, 2025 0

Funding granted to researchers by the National Institutes of Health powered $94....

Siemens Healthineers expands photon-counting CT family with new FDA clearances

Siemens Healthineers expands photon-counting CT family ...

Mar 11, 2025 0

Siemens Healthineers aims to bring photon-counting technology to single-source C...

NIH grants powered $94B in economic activity in 2024 and supported more than 400,000 jobs: report

NIH grants powered $94B in economic activity in 2024 an...

Mar 11, 2025 0

Funding granted to researchers by the National Institutes of Health (NIH) powere...

Illumina aims to cut $100M in costs following China import ban

Illumina aims to cut $100M in costs following China imp...

Mar 11, 2025 0

Illumina also lowered its annual financial forecast, as it plans to deal with a ...

Daiichi taps Nosis to deliver RNA therapies beyond the liver

Daiichi taps Nosis to deliver RNA therapies beyond the ...

Mar 11, 2025 0

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis ...

Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader

Pfizer, Arvinas post mixed breast cancer survival resul...

Mar 11, 2025 0

Pfizer and Arvinas’ estrogen receptor degrader has failed a key part of its firs...

Mineralys' stock jumps as hypertension drug posts double clinical wins

Mineralys' stock jumps as hypertension drug posts doubl...

Mar 11, 2025 0

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase i...

Coherus to lose 30% of staff as part of Udenyca sale to Accord

Coherus to lose 30% of staff as part of Udenyca sale to...

Mar 11, 2025 0

Coherus BioSciences will see its workforce shrink once again as a result of the ...

Agomab's ALK5 inhibitor hits target in phase 2 Crohn's disease trial

Agomab's ALK5 inhibitor hits target in phase 2 Crohn's ...

Mar 11, 2025 0

Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the...

Canadian CRO Innovaderm rebrands to Indero to reflect expanded rheumatology focus

Canadian CRO Innovaderm rebrands to Indero to reflect e...

Mar 11, 2025 0

Montreal-based CRO Innovaderm Research has rebranded with immediate effect to In...

NIH unveils plan to centralize grant reviews in effort to save $65M-plus annually

NIH unveils plan to centralize grant reviews in effort ...

Mar 10, 2025 0

The National Institutes of Health unveiled a plan on March 6 to move the peer re...

J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data

J&J opts out of licensing Genmab's Darzalex challenger ...

Mar 10, 2025 0

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 m...

Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients

Immunocore T-cell engager clears safety hurdle, reduces...

Mar 10, 2025 0

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. N...

Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analyst

Beam gene therapy for protein deficiency passes early s...

Mar 10, 2025 0

Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 tri...

J&J opts out of licensing Genmab’s Darzalex challenger after look at phase 1/2 data

J&J opts out of licensing Genmab’s Darzalex challenger ...

Mar 10, 2025 0

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 m...

Fierce Biotech Fundraising Tracker '25: Lila launches with $200M; Garuda grabs $50M series A

Fierce Biotech Fundraising Tracker '25: Lila launches w...

Mar 10, 2025 0

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

With $200M in seed funding, Flagship-backed Lila Sciences touts ambitious AI vision

With $200M in seed funding, Flagship-backed Lila Scienc...

Mar 10, 2025 0

Biotech incubator Flagship Pioneering has uncorked its latest company. Lila Scie...

Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analysts

Beam gene therapy for protein deficiency passes early s...

Mar 10, 2025 0

Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 tri...

Dexcom receives FDA warning letter over CGM manufacturing issues

Dexcom receives FDA warning letter over CGM manufacturi...

Mar 10, 2025 0

Dexcom has received a warning letter from the FDA, following two inspections of ...

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort

Arrowhead finds RNAi kidney disease candidate is well t...

Mar 10, 2025 0

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigatio...

Mineralys’ stock jumps as hypertension drug posts double clinical wins

Mineralys’ stock jumps as hypertension drug posts doubl...

Mar 10, 2025 0

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase i...

13
14
15
16
17

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.